Also known as: BRAF V600E mutation
A case series of three Erdheim-Chester disease patients demonstrates the disease's diagnostic challenges, with one patient improving on targeted BRAF inhibition while two others died within a year. The rare histiocytosis often presents with multisystem involvement, delaying diagnosis.
Phase 3 BREAKWATER found encorafenib plus cetuximab plus FOLFIRI improved PFS and response in first-line BRAF V600E-mutant metastatic colorectal cancer. OS data remain immature.
A real-world analysis found BRAF V600E-mutated papillary thyroid cancer had a proinflammatory molecular profile, but no significant overall survival difference versus BRAF wild-type disease. Treatment choice among BRAF/MEK inhibitors, tyrosine kinase inhibitors, and immunotherapy was not associated with significant survival differences.
Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.
Pfizer reported new clinical and regulatory milestones across oncology, obesity and hemophilia, including BREAKWATER Phase 3 data and Priority Review for HYMPAVZI. The company also cited MagnetisMM-5 results and FDA priority review for PADCEV.
A study finds nearly half of melanoma patients receiving BRAF or MEK inhibitors develop hypertension or cardiac dysfunction. Moderate to severe cardiac issues appear within 4 weeks and only in patients with medium or higher baseline risk. Higher baseline NT-proBNP levels are associated with increased cardiac dysfunction risk.
Atezolizumab combined with chemotherapy shows significant benefits in dMMR/MSI-H colorectal cancer. In stage III disease, the ATOMIC trial demonstrated improved 3-year DFS (86.3% vs 76.2%) with atezolizumab plus mFOLFOX6. For metastatic disease, the COMMIT trial showed superior PFS (24.5 vs 5.3 months) with atezolizumab, bevacizumab, and FOLFOX versus atezolizumab monotherapy.
Elicio Therapeutics granted inducement stock options to new employees, with one grant of 1,600 options at $12.16 per share and another of 30,300 options at $8.59 per share. The clinical-stage biotech company is developing novel immunotherapies targeting mKRAS-positive cancers, with its ELI-002 program showing promising Phase 1 results including 16.3-month median recurrence-free survival.
Hanmi Pharmaceutical has initiated phase 2 patient dosing of belvarafenib for NRAS-mutated melanoma in Korea, enrolling the first patient at a university hospital. The multicenter trial will evaluate combination therapy in 45 patients with locally advanced or metastatic disease.
Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.
